Next Article in Journal
Degenerative Cervical Myelopathy: A Brief Review of Past Perspectives, Present Developments, and Future Directions
Next Article in Special Issue
Is Hematopoietic Stem Cell Transplantation Required to Unleash the Full Potential of Immunotherapy in Acute Myeloid Leukemia?
Previous Article in Journal
Subacute Thyroiditis is Associated with HLA-B*18:01, -DRB1*01 and -C*04:01—The Significance of the New Molecular Background
Previous Article in Special Issue
Highly Sensitive Detection of IDH2 Mutations in Acute Myeloid Leukemia
Open AccessArticle

Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia

1
Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD 21201, USA
2
School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA
3
School of Medicine, University of Maryland, Baltimore, MD 21201, USA
4
School of Medicine, University of Virginia, Charlottesville, VA 22908, USA
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(2), 536; https://doi.org/10.3390/jcm9020536
Received: 10 January 2020 / Revised: 9 February 2020 / Accepted: 13 February 2020 / Published: 16 February 2020
(This article belongs to the Special Issue Advances in Acute Myeloid Leukemia)
Currently, no standard of care exists for the treatment of relapsed or refractory acute myeloid leukemia (AML). We present our institutional experience with using either CLAG-M or HAM-pegA, a novel regimen that includes pegaspargase. This is a retrospective comparison of 34 patients receiving CLAG-M and 10 receiving HAM-pegA as first salvage cytotoxic chemotherapy in the relapsed or refractory setting. Composite complete response rates were 47.1% for CLAG-M and 90% for HAM-pegA (p = 0.027). Event-free survival was significantly different in favor of HAM-pegA (p = 0.045), though overall survival was similar between groups. There were no significant differences in toxicities experienced by patients treated with the two regimens, including adverse events of special interest related to pegaspargase (venous thromboembolism, hemorrhage, hepatotoxicity, pancreatitis, and hypersensitivity reactions). HAM-pegA is a novel regimen for relapsed or refractory AML that resulted in improved response rates and similar toxicities compared to CLAG-M. View Full-Text
Keywords: acute myeloid leukemia; relapsed; refractory; CLAG-M; HAM-pegA; asparaginase acute myeloid leukemia; relapsed; refractory; CLAG-M; HAM-pegA; asparaginase
Show Figures

Figure 1

MDPI and ACS Style

Patzke, C.L.; Duffy, A.P.; Duong, V.H.; El Chaer, F.; Trovato, J.A.; Baer, M.R.; Bentzen, S.M.; Emadi, A. Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia. J. Clin. Med. 2020, 9, 536.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop